A Phase Ib/II Study of APG-115 Alone or in Combination with Azacitidine in Patients with Relapse/Refractory AML
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Ascentage Pharma Group
Start Date
February 22, 2021
End Date
March 14, 2026
Administered By
Duke Cancer Institute
Awarded By
Ascentage Pharma Group
Start Date
February 22, 2021
End Date
March 14, 2026